Research-grade sourcing is a major risk in the peptide market
Our professionals are dedicated to leading you on a tailored path to vitality, providing insights, care, and cutting-edge therapies
With the backing of 20 industry bodies and organisations, it is a culmination of robust discussions and broad consensus developed at the National Kidney Summit
Side effects are more likely in: First-time peptide users Individuals starting at higher doses Those stacking ipamorelin with other growth hormone peptides People with insulin sensitivity concerns Individuals with unbalanced hormones before starting treatment This is why personalized guidance matters
Skrtic S, Wallenius V, Ekberg S, Brenzel A, Gressner AM, Jansson JO: Insulin-like growth factors stimulate expression of hepatocyte growth factor but not transforming growth factor beta1 in cultured hepatic stellate cells
Cutan Ocul Toxicol